156 related articles for article (PubMed ID: 20870258)
21. Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group.
Laguna F; López-Vélez R; Pulido F; Salas A; Torre-Cisneros J; Torres E; Medrano FJ; Sanz J; Picó G; Gómez-Rodrigo J; Pasquau J; Alvar J
AIDS; 1999 Jun; 13(9):1063-9. PubMed ID: 10397536
[TBL] [Abstract][Full Text] [Related]
22. Antimony in plasma and skin of patients with cutaneous leishmaniasis--relationship with side effects after treatment with meglumine antimoniate.
Neves DB; Caldas ED; Sampaio RN
Trop Med Int Health; 2009 Dec; 14(12):1515-22. PubMed ID: 19954451
[TBL] [Abstract][Full Text] [Related]
23. [N-methyl glucamine antimoniate or Glucantime].
Rapp C; Simon F; Dordain ML
Med Trop (Mars); 2000; 60(4):342-3. PubMed ID: 11436584
[No Abstract] [Full Text] [Related]
24. Comparison of generic to branded pentavalent antimony for treatment of new world cutaneous leishmaniasis.
Soto J; Valda-Rodriquez L; Toledo J; Vera-Navarro L; Luz M; Monasterios-Torrico H; Vega J; Berman J
Am J Trop Med Hyg; 2004 Nov; 71(5):577-81. PubMed ID: 15569787
[TBL] [Abstract][Full Text] [Related]
25. Successful treatment of visceral leishmaniasis with allopurinol plus ketoconazole in an infant who developed pancreatitis caused by meglumine antimoniate.
Kuyucu N; Kara C; Bakirtaç A; Teziç T
Pediatr Infect Dis J; 2001 Apr; 20(4):455-7. PubMed ID: 11332679
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of three chemotherapeutic schemes with meglumine antimoniate in the treatment of visceral leishmaniasis in the State of Pará, Brazil.
Marsden PD
Rev Inst Med Trop Sao Paulo; 1993; 35(6):589. PubMed ID: 7997767
[No Abstract] [Full Text] [Related]
27. Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya.
Moore E; O'Flaherty D; Heuvelmans H; Seaman J; Veeken H; de Wit S; Davidson RN
Bull World Health Organ; 2001; 79(5):388-93. PubMed ID: 11417033
[TBL] [Abstract][Full Text] [Related]
28. Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis.
Gasser RA; Magill AJ; Oster CN; Franke ED; Grögl M; Berman JD
Clin Infect Dis; 1994 Jan; 18(1):83-90. PubMed ID: 7519887
[TBL] [Abstract][Full Text] [Related]
29. High parasitological failure rate of visceral leishmaniasis to sodium stibogluconate among HIV co-infected adults in Ethiopia.
Diro E; Lynen L; Mohammed R; Boelaert M; Hailu A; van Griensven J
PLoS Negl Trop Dis; 2014 May; 8(5):e2875. PubMed ID: 24854196
[TBL] [Abstract][Full Text] [Related]
30. A randomized clinical trial comparing oral azithromycin and meglumine antimoniate for the treatment of American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis.
Krolewiecki AJ; Romero HD; Cajal SP; Abraham D; Mimori T; Matsumoto T; Juarez M; Taranto NJ
Am J Trop Med Hyg; 2007 Oct; 77(4):640-6. PubMed ID: 17978064
[TBL] [Abstract][Full Text] [Related]
31. Drug hypersensitivity syndrome induced by meglumine antimoniate.
Jeddi F; Caumes E; Thellier M; Jauréguiberry S; Mazier D; Buffet PA
Am J Trop Med Hyg; 2009 Jun; 80(6):939-40. PubMed ID: 19478253
[TBL] [Abstract][Full Text] [Related]
32. [Agranulocytosis caused by glucantime (N-methylglucamine antimoniate) during treatment of kala-azar].
Gutiérrez Rodero F; Moya Jeromini I; Ortiz de la Tabla Ducasse V; Pozuelo González A
Med Clin (Barc); 1985 May; 84(20):840. PubMed ID: 4033266
[No Abstract] [Full Text] [Related]
33. Relapse in Ethiopian visceral leishmaniasis (VL) patients after therapy with pentavalent antimonials: a ten year observation.
Berhe N; Ali A; Hailu A; Yeneneh H
Acta Trop; 1994 Jun; 57(1):83-90. PubMed ID: 7942358
[TBL] [Abstract][Full Text] [Related]
34. Acute pancreatitis associated with the administration of meglumine antimonate for the treatment of visceral leishmaniasis.
de Lalla F; Pellizzer G; Gradoni L; Vespignani M; Franzetti M; Stecca C
Clin Infect Dis; 1993 May; 16(5):730-1. PubMed ID: 8507769
[No Abstract] [Full Text] [Related]
35. Clinical aspects of paediatric visceral leishmaniasis in North-west Ethiopia.
Diro E; Lynen L; Gebregziabiher B; Assefa A; Lakew W; Belew Z; Hailu A; Boelaert M; van Griensven J
Trop Med Int Health; 2015 Jan; 20(1):8-16. PubMed ID: 25329449
[TBL] [Abstract][Full Text] [Related]
36. Risk factors associated with dizziness during treatment of mucosal leishmaniasis with meglumine antimoniate: 16-year retrospective study of cases from Rio de Janeiro, Brazil.
Araujo-Melo MH; Meneses AM; Schubach AO; Moreira JS; Conceição-Silva F; Salgueiro MM; Pimentel MI; Araújo-Silva M; Oliveira RV; Carmo CN; Valete-Rosalino CM
J Laryngol Otol; 2010 Oct; 124(10):1056-60. PubMed ID: 20537206
[TBL] [Abstract][Full Text] [Related]
37. Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome.
ter Horst R; Collin SM; Ritmeijer K; Bogale A; Davidson RN
Clin Infect Dis; 2008 Jun; 46(11):1702-9. PubMed ID: 18419422
[TBL] [Abstract][Full Text] [Related]
38. Acute pancreatitis caused by meglumine antimoniate given for the treatment of visceral leishmaniasis.
Lambertucci JR; França BM; Queiroz Ede M
Rev Soc Bras Med Trop; 2004; 37(1):74-5. PubMed ID: 15042193
[No Abstract] [Full Text] [Related]
39. Pediatric visceral leishmaniasis in Western Sicily, Italy: a retrospective analysis of 111 cases.
Cascio A; Colomba C; Antinori S; Orobello M; Paterson D; Titone L
Eur J Clin Microbiol Infect Dis; 2002 Apr; 21(4):277-82. PubMed ID: 12072938
[TBL] [Abstract][Full Text] [Related]
40. Successful treatment of non-healing cases of cutaneous leishmaniasis, using a combination of meglumine antimoniate plus allopurinol.
Momeni AZ; Aminjavaheri M
Eur J Dermatol; 2003; 13(1):40-3. PubMed ID: 12609780
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
